PROTEOMICS INTERNATIONAL LABOR ORD
Proteomics International Confirms US Reimbursement Price for ProMarkerD Diabetic Kidney Disease Test
Proteomics International Laboratories (ASX: PIQ) has announced that the US Centres for Medicare & Medicaid Services has set a US$390.75 reimbursement price for its PromarkerD predictive test for diabetic kidney disease.
Proteomics International Gains ISO 15189 Certification for Precision Diagnostics Operations
Proteomics International (ASX: PIQ) has achieved a significant milestone with the granting of ISO 15189 certification for its Australian laboratory operations. The medical testing certification – which adds to Proteomics’ existing ISO 17025, ISO 13485 and CLIA certifications – will assist the company in commercialisation and clinical use of its suite of precision diagnostic tests, […]
Proteomics International Laboratories launches PromarkerD predictive test for diabetic kidney disease
Proteomics International Laboratories (ASX: PIQ) has officially launched its unique PromarkerD predictive test for diabetic kidney disease in Australia. PromarkerD is a clinically validated blood test that helps predict the risk of developing chronic diabetic kidney disease (DKD) in type 2 diabetes patients up to four years before clinical symptoms appear. Diabetes is the leading […]
Proteomics International Laboratories’ PromarkerD test paving the way for early detection of diabetic kidney disease
Proteomics International Laboratories (ASX: PIQ) has obtained what it describes as “groundbreaking” results in its development of treatments for deadly type 1 diabetes. More than 130,000 Australians live with type 1 diabetes, which currently accounts for around 10% of the nation’s diabetes cases and cannot be prevented. Globally, diabetes has emerged as the largest single […]